The US Patent and Trademark Office has awarded Titan Spine with four new patents relating to the surface technology and design of the company’s Endoskeleton interbody devices and specialised system instrumentation.
A company press release reported that the most recent patent (patent No. 8,480,749) was received on 9th July for aspects of the company’s roughened implant surface, which features a unique combination of macro, micro and cellular-level textures that has been shown to help induce the production of biologically active proteins necessary for bone growth. Therefore, in total, Titan Spine now holds 10 patents, with an additional 14 applications under review and expected to be awarded this year.
According to the press release, Titan Spine applies a proprietary treatment to its titanium devices to produce a textured surface that creates the ideal surface energy for enhanced bone production at the fusion site. This surface technology is featured on Titan’s full line of Endoskeleton interbody devices for the cervical and lumbar spine. Additional aspects of the Endoskeleton platform protected by these new patents include the devices’ unique shape, designed to rest on the apophyseal ring of the vertebral endplate for strength and stability, and large windows for increased bone graft volumes and improved radiographic visualisation and fusion evaluation.
Paul Slosar, orthopaedic surgeon at SpineCare Medical Group and the San Francisco Spine Institute in San Francisco, USA, and medical director for Titan Spine, commented, “The science behind Titan Spine’s implants is translating into significant clinical benefits. In my experience, patients are fusing more quickly and exhibiting robust fusion, with meaningful, sustained pain reduction and functional improvement. While traditional interbody cages serve mainly to provide structure to the fusion site, Titan’s devices also enhance the fusion process and represent the future of spine implant development.”